Quest Diagnostics stock falls as Medicare cuts threaten 2027 earnings

Published on 09/22/2026 at 18:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Quest Diagnostics stock faced a proposed 15 percent Medicare fee cut on September 22, 2026. Second-quarter EPS reached USD 3.12 against USD 2.82 expected.

Automatisierter Laboranalysator mit Blutproben-Röhrchen in klinischem Diagnostiklabor — Quest Diagnostics US74834L1008 zeigt automatisierten Laboranalysator mit Blutproben in modernem Diagnostiklabor fotorealistisch dargestellt, Illustration mit AI erstellt.

Quest Diagnostics stock (ISIN US74834L1008) faced a proposed Medicare reimbursement cut of up to 15 percent from January 1, 2027, after reaching an intraday 52-week high of USD 248.84 on September 21, 2026. The regulatory proposal shifted attention from the company's recent earnings momentum to the potential effect on routine laboratory testing.

Medicare proposal changes the setup

According to Yahoo Finance on September 22, 2026, preliminary proposals from the Centers for Medicare and Medicaid Services could reduce laboratory fee payments by as much as 15 percent starting January 1, 2027. The same report said the shares fell 6.9 percent in premarket trading after the proposal, while a Truist Securities note maintained a Hold rating and raised its price target to USD 260 from USD 250.

The potential cut matters because the reimbursement pressure would affect a recurring part of diagnostic testing revenue rather than a one-off project. Investing.com reported on September 22, 2026, that Evercore estimated a USD 90 million to USD 100 million adjusted operating-income impact in 2027 and described the effect as a low-to-mid single-digit earnings-per-share headwind.

Quarterly figures remain supportive

The latest reported quarter still provides a counterweight to the reimbursement risk. Quest Diagnostics generated revenue of USD 3.04 billion in the second quarter of 2026, while adjusted earnings per share reached USD 3.12 versus a consensus estimate of USD 2.82, according to Investing.com on September 22, 2026. The EPS result was USD 0.30 above the cited expectation, a quantified beat that helps explain why analysts continued to raise targets despite the policy risk.

Investing.com reported on September 22, 2026, that Truist Securities lifted its target from USD 225 to USD 250 while retaining a Hold rating, and that UBS raised its target from USD 232 to USD 245 while keeping a Neutral rating. Those increases contrast with the proposed reimbursement changes and show that recent operating performance remains part of the valuation debate.

Stock remains near yearly high

Quest Diagnostics traded between USD 243.70 and USD 248.84 during the NYSE session on September 21, 2026, according to the session data cited in the available market report. The stock then reached USD 232.12 in after-hours trading after the Medicare proposal, a move that placed policy sensitivity directly beside the recent 52-week high.

Market capitalization was reported at USD 25.93 billion on September 22, 2026, while the year-to-date price return stood at 43 percent, according to Investing.com. The combination of a 43 percent year-to-date gain and a potential 15 percent reimbursement reduction leaves the stock exposed to a sharper debate over earnings durability in 2027.

Policy risk now sets the next test

Quest Diagnostics closed at USD 246.48 on September 22, 2026, on the NYSE, according to the available market snapshot, with the stock still close to the reported 52-week high of USD 248.84. The central market question is whether the company's USD 3.12 second-quarter adjusted EPS and raised 2026 outlook can offset the proposed 2027 reimbursement pressure.